This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
The 24th March is World TB Day, a day that is of considerable relevance to many imprisoned across the world.
"Due to overcrowding and poor nutrition, the tuberculosis notification rate in prisons ranges from 11 to 81 times higher than in the community outside prisons." World Health Organization (WHO)
World TB day BLOG: Tackling tuberculosis in under-served populations https://publichealthmatters.blog.gov.uk/2019/03/22/tackling-tuberculosis-in-under-served-populations/
End TB Strategy: https://www.who.int/tb/strategy/end-tb/en/
- Tuberculosis (TB) is one of the top 10 causes of death worldwide.
- In 2017, 10 million people fell ill with TB, and 1.6 million died from the disease (including 0.3 million among people with HIV).
- In 2017, an estimated 1 million children became ill with TB and 230 000 children died of TB (including children with HIV associated TB).
- TB is a leading killer of HIV-positive people.
- Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. WHO estimates that there were 558 000 new cases with resistance to rifampicin – the most effective first-line drug, of which - 82% had MDR-TB.
- Globally, TB incidence is falling at about 2% per year. This needs to accelerate to a 4–5% annual decline to reach the 2020 milestones of the End TB Strategy.
- An estimated 54 million lives were saved through TB diagnosis and treatment between 2000 and 2017.
Ending the TB epidemic by 2030 is among the health targets of the Sustainable Development Goals.
https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis World Health Organization (WHO)
Latest Research (2018-19):
Rapid tests reduce the burden of tuberculosis in Azerbaijan prisons: special emphasis on rifampicin-resistance
Gurbanova, Elmira & Mehdiyev, Rafail & Blondal, Kai & Altraja, Alan. (2018). Rapid tests reduce the burden of tuberculosis in Azerbaijan prisons: special emphasis on rifampicin-resistance. 20. 111-120.
Evaluating strategies for control of Tuberculosis in Prisons and prevention of spillover into communities: An observational and modeling study from Brazil
Mabud TS, de Lourdes Delgado Alves M, Ko AI, Basu S, Walter KS, Cohen T, et al. (2019) Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil. PLoS Med 16(1): e1002737. https://doi.org/10.1371/journal.pmed.1002737
High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
Schmit, Kristine M., MD; Lobato, Mark N., MD; Lang, Simona G., MPH; Wheeler, Sherri, DNP; Kendig, Newton E., MD; Bur, Sarah, MPH. Journal of Public Health Management and Practice: March/April 2019 - Volume 25 - Issue 2 - p E1–E6
Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area
Senia Rosales-Klintz, Judith Bruchfeld, Walter Haas, Einar Heldal, Rein M.G.J. Houben, Femke van Kessel, Mike Mandelbaum, Alberto Matteelli, Giovanni Battista Migliori, Anouk Oordt-Speets, Ivan Solovic, Martina Vašáková, Suzanne Verver, Sake J. de Vlas, Marije J.M. Vonk Noordegraaf-Schouten, Gerard de Vries, Dominik Zenner, Marieke J. van der WerfEuropean Respiratory Journal 2019 53: 1802077; DOI: 10.1183/13993003.02077-2018
HIV/TB/HCV services for incarcerated populations in Azerbaijan and the EECA region.
The tide of HIV, hepatitis C virus (HCV) and drug-resistant tuberculosis (DR-TB) is a challenge for the penitentiary system (PS) in Eastern Europe Central Asia (EECA) region. We have analyzed the existing services for incarcerated individuals with HIV, HCV, and TB to assess the current situation in the EECA region.
Mehdiyev R, Alikhanova N, Gurbanova E. HIV/TB/HCV services for incarcerated populations in Azerbaijan and the EECA region. Curr Opin HIV AIDS. 2019;14(1):66-70.
Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons.
Gurbanova E, Mehdiyev R, Blondal K, Altraja A. Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons. Eur Respir J.2018;52 (Suppl 62). Tees nr PA3680.